SMART Brain Health in African-Americans

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Opioid Use Disorder, Substance Use Disorders, Dopamine Dysregulation Syndrome, African Americans

In brief

The investigators hypothesize that opioid use in African-Americans will be associated with hypodopaminergic alleles that alter the threshold for activating feelings of reward and pleasure within the dopaminergic system, and that these allelic frequencies will differ significantly from European Americans. Planned is a targeted system to study genetic risks for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS), comprehensive surveys to determine quality of life and exposure to stressors and trauma. This system will allow prediction of addiction and relapse potential and delivery of personalized treatment.

Key facts

Study ID

NCT03861832

Run by

Howard University

People needed

140

Starts

2018-06-16

Expected to finish

2019-08-30

Last updated by the study team

2019-03-04

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must be able to consent and understand questions being asked during surveys
• Must be willing to undergo pharmacogenetic testing
• Must be able to swallow tablets

You may not qualify if…

• Clinical Diagnosis of Alzheimer's disease/Dementia
• Clinical Diagnosis of Schizophrenia
• Clinical Diagnosis of a terminal disorder

Where it is running

• Howard University — Washington D.C., District of Columbia, United States (enrolling)
• Medical Home Development Group — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.